Guest guest Posted November 6, 2010 Report Share Posted November 6, 2010 In today's edition of Caring for Cancer (11-5-10) it announced the results of a comparison between Gleevec and Sprycel in how fast patients responded. ================ FDA news release [published by www.CancerConsultants.com] " Gleevec produces high rates of remission among patients with chronic-phase CML, often with few side effects, and has dramatically changed the treatment of this disease. " Sprycel and Tasigna® (nilotinib) are two oral second-generation drugs that also target the BRC-ABL protein and were previously approved for CML patients who were resistant or intolerant to Gleevec. " To compare Sprycel with Gleevec in the initial treatment of CML, researchers conducted a study among 519 patients with newly diagnosed Philadelphia chromosome-positive chronic-phase CML. Patients were randomized to undergo treatment with either Gleevec or Sprycel. " One of the main outcomes of interest was the complete cytogenetic response rate. A complete cytogenetic response is the complete disappearance of cells with the Philadelphia chromosome. a.. After one year, the complete cytogenetic response rate was 77% among patients treated with Sprycel and 66% among patients treated with Gleevec. b.. Rates of major molecular response (another marker of drug effectiveness) were 52% among patients treated with Sprycel and 34% among patients treated with Gleevec. c.. Both drugs were generally well tolerated. " These results suggest that Sprycel may be more effective than Gleevec for the initial treatment of CML. Sprycel provides another treatment option for newly diagnosed Philadelphia chromosome-positive chronic-phase CML patients. " http://tinyurl.com/38qz52n ================== Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.